[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576225":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":56,"collaborators":25,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Dose Group","ACTIVE_COMPARATOR","Patients with knee osteoarthritis who are interested in knee intra-articular corticosteroid injections and meet the inclusion criteria.",[13],"Drug: Triamcinolone Acetonide Standard Dose",{"label":15,"type":16,"description":11,"interventionNames":17},"Lower Dose Group","EXPERIMENTAL",[18],"Drug: Triamcinolone Acetonide Low Dose",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Triamcinolone Acetonide Low Dose","Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.\n\nTotal injection volume of 5ml, consisting of:\n\n* 0.5ml triamcinolone acetonide (20mg)\n* 4.5ml lidocaine (45mg)",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Triamcinolone Acetonide Standard Dose","Subjects will receive the standard of care dose of 40mg triamcinolone acetonide\n\nTotal injection volume of 5ml, consisting of:\n\n* 1ml triamcinolone acetonide (40mg)\n* 4ml lidocaine (40mg)",[9],[31],{"name":32,"affiliation":5,"role":33},"Jeffrey P Nadwodny, DO","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","904 953 6722","nadwodny.jeffrey@mayo.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Mayo Clinic in Florida","RECRUITING","Jacksonville","Florida","32224","United States",{"type":48,"coordinates":49},"Point",[50,51],-81.65565,30.33218,{"lat":51,"lon":50},[54,55],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Jeff P. Nadwodny","Assistant Professor of Family Medicine","100576225",false,"NCT06782529","Knee Injections for Obese Patients With Knee Arthritis","Comparison of Varying Doses of Steroid for Intra-articular Knee Injections","Inclusion Criteria:\n\n• Patients with BMI ≥30 kg\u002Fm2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis.\n\nExclusion Criteria:\n\n* BMI \\\u003C 30 kg\u002Fm2\n* Uncontrolled diabetics with a hemoglobin A1c \\> 8%\n* No other treatment within the time frame of the study.\n* Patients that are undergoing physical therapy at the time of the study.","ALL","55 Years","85 Years",{"count":69,"type":70},40,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.",[76],"Osteoarthritis of Knee",[78,79,80],"Knee Osteoarthritis","Corticosteroid Injection","Obesity","2026-03-06",{"date":83,"type":84},"2026-03-10","ACTUAL",{"date":86,"type":84},"2025-01-24",{"date":88,"type":70},"2027-01-24",{"name":5,"class":6},1]